Karo Bio's next act
Pfizer deal unlocks value in Karo Bio's preclinical programs
Eprotirome, a thyroid hormone receptor agonist, is in the Phase III AKKA trial in 630 patients with heterozygous familial hypercholesterolemia (HeFH). Interim three-month data from the first 150 patients are expected in 2Q12.
Last October, Karo Bio decided to spin out its preclinical operations into a subsidiary to separate them from eprotirome and to sharpen the company's focus, President and CEO Per Bengtsson told BioCentury. "It's